Vir Biotechnology Inc.

4 days ago · defenseworld.net

Engineers Gate Manager LP trimmed its stake in Vir Biotechnology, Inc. (NASDAQ: VIR) by 48.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,427 shares of the company's stock after selling 121,964 shares during the period. Engineers Gate Manager LP owned

2 months ago · seekingalpha.com

Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript

2 months ago · marketbeat.com

Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500.

2 months ago · zacks.com

Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to a loss of $0.8 per share a year ago.

2 months ago · businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O'Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer."Brent has deep in.

2 months ago · businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powe.

2 months ago · seekingalpha.com

Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIPSE program in hepatitis delta plus updates from its T-cell engagers in oncology indications. VIR has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for prostate cancer. Updated data from VIR-5818 are due in H2'26 and could include a further ~18 months of data.

3 months ago · businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has he.

4 months ago · businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phas.

4 months ago · fool.com

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.